Company: ARMP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077648
Chunk: 16

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 16
---
 our securities
involves a high degree of risk. Prior to making a decision about investing in our securities, you should carefully consider the specific
risk factors discussed in the sections entitled “Risk Factors” contained in our annual report on Form 10-K for the fiscal year ended December 31, 2024 under the heading “Item 1A. Risk Factors,” and as described or may be described in any subsequent
quarterly report on Form 10-Q under the heading “Item 1A. Risk Factors,” as well as in any applicable prospectus supplement
and contained or to be contained in our filings with the SEC and incorporated by reference in this prospectus, together with all of the
other information contained in this prospectus, or any applicable prospectus supplement. For a description of these reports and documents,
and information about where you can find them, see “Where You Can Find More Information” and “Incorporation of Certain
Information by Reference.” If any of the risks or uncertainties described in our SEC filings or any prospectus supplement or any
additional risks and uncertainties actually occur, our business, financial condition and results of operations could be materially and
adversely affected.

In that case, the trading
price of our securities could decline and you might lose all or part of the value of your investment.

<div align='center'>8

THE SECURITIES WE MAY OFFER</div>

We may offer up to $100,000,000
of shares of our common stock, preferred stock, debt securities, warrants or units in any combination of the foregoing, under this prospectus
at prices and on terms to be determined by market conditions at the time of offering. This prospectus provides you with a general description
of the securities we may offer. Each time we offer a type or series of securities, we will provide a prospectus supplement that will describe
the specific amounts, prices and other important terms of the securities.

A prospectus supplement and
any related free writing prospectus that we may authorize to be provided to you also may add, update or change information contained in
this prospectus or in documents we have incorporated by reference.

This prospectus may not be used to offer or sell securities unless it is accompanied by a prospectus supplement.

We may sell the securities
directly to or through agents, underwriters or dealers. We, and our agents, dealers or underwriters, reserve the right to accept or reject
all or part of any proposed purchase of securities. If